Metformin-associated lactic acidosis: Bridging pharmacokinetic determinants, metabolic pathways, and clinical outcomes.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms, risk factors, and management without systematic search methodology.
PubMed 42178010 · doi:10.1016/j.ejphar.2026.179017
What was done
This narrative review synthesized the pathophysiological mechanisms, pharmacokinetic determinants, diagnostic markers, predisposing clinical conditions, and management strategies associated with metformin-associated lactic acidosis (MALA).
What was found
The authors report that MALA is characterized by high anion-gap metabolic acidosis, blood lactate concentrations above 5 mmol/L, and arterial pH below 7.35. The underlying mechanism is primarily driven by mitochondrial complex I inhibition, which alters the intracellular redox state and impairs hepatic lactate clearance. The condition acts as an accumulation disorder typically precipitated by an acute decline in renal function or comorbidities (such as acute kidney injury, chronic kidney disease, sepsis, dehydration, hypoxia, and hepatic impairment) rather than toxicity at normal therapeutic levels. Recommended management includes immediate drug cessation, supportive measures, and renal replacement therapy in severe cases. Specific empirical event rates, mortality percentages, and comparative trial numbers were not reported in the abstract.
Why it matters
It consolidates clinical recognition criteria, pathophysiologic pathways, and prevention strategies—such as dose adjustments and sick-day medication pauses—to mitigate severe outcomes in patients prescribed first-line metformin therapy.
Limits
The abstract describes a narrative overview rather than a systematic review or meta-analysis. No primary clinical datasets, sample sizes, effect estimates, or quantitative comparisons of different treatment regimens are provided.
Cited by
- supports Metformin can cause lactic acidosis, particularly at higher doses or in patients with renal insufficiency or impaired liver function.